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Abstract
Background: Gastrointestinal	symptom-specific	anxiety	and	somatization	have	both	
been associated with higher symptom severity in patients with irritable bowel syn-
drome	 (IBS);	however,	 this	 relationship	has	not	been	explored	 fully.	Moreover,	 the	
performance	 of	 the	 visceral	 sensitivity	 index	 (VSI)	 for	 measuring	 gastrointestinal	
symptom-specific	anxiety	has	not	been	examined	in	a	UK	population.	We	conducted	
a	cross-sectional	survey	to	examine	these	issues.
Methods: Gastrointestinal	 symptom-specific	 anxiety	was	measured	using	 the	VSI,	
and	somatization	was	measured	via	the	patient	health	questionnaire-12	(PHQ-12)	in	
adults	from	the	UK	community	with	Rome	IV-defined	IBS.	Exploratory	factor	analysis	
was	performed	on	the	VSI,	prior	to	subsequent	analyses,	to	establish	its	factor	struc-
ture.	Multiple	regression	analysis	was	used	to	determine	the	relationship	between	
demographic	features,	different	factors	of	the	VSI,	somatization,	and	IBS	symptom	
severity.
Key Results: A	total	of	811	individuals	with	IBS	provided	complete	data.	Factor	analy-
sis	of	the	VSI	revealed	a	three-factor	structure,	accounting	for	47%	of	the	variance.	
The	first	of	these	VSI	factors	and	the	PHQ-12	were	both	strongly	and	independently	
associated	with	IBS	symptom	severity,	for	the	group	as	a	whole	and	for	all	four	IBS	
subtypes.	Most	VSI	 items	concerned	with	overt	gastrointestinal	 symptom-specific	
anxiety	loaded	onto	the	other	two	VSI	factors	that	were	not	associated	with	symp-
tom severity.
Conclusions and Inferences: The	 factor	 structure	 of	 the	 VSI	 requires	 further	 in-
vestigation. Our findings cast doubt on the central role of gastrointestinal symp-
tom-specific	 anxiety	 as	 a	 driver	 for	 symptom	 severity	 in	 IBS.	 Awareness	 of	 both	
gastrointestinal	and	extra-intestinal	symptoms,	however,	is	strongly	associated	with	
symptom severity.
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1  | INTRODUC TION
Irritable	bowel	syndrome	(IBS)	is	a	functional	bowel	disorder,	charac-
terized	by	abdominal	pain,	in	association	with	defecation	or	a	change	
in bowel habit.1 The prevalence in the community has previously 
been	estimated	to	be	10%,2 but in a recent study applying the Rome 
IV	criteria	in	a	UK	and	North	American	population,	the	prevalence	
was	lower,	at	around	5%.3 The condition is commoner in women and 
younger individuals.2,4	 IBS	 accounts	 for	 a	 considerable	proportion	
of referrals to gastroenterology across both secondary and tertiary 
care	settings,5	and	direct	costs	in	the	USA	have	been	estimated	at	
almost	$1	billion,	with	another	$50	million	in	indirect	costs.6
Although	 there	 are	 effective	 therapies	 available	 to	 treat	 some	
of	the	symptoms	of	IBS,7 there is no “cure” for sufferers. The chro-
nicity	of	symptoms,	which	can	fluctuate	over	time,8 may therefore 
impact	on	work	and	social	functioning,9 and eating habits.10 This in 
turn	may	have	deleterious	consequences	for	both	quality	of	life	and	
mood.9-11	The	quality	of	life	of	people	with	IBS	is	impaired	to	a	similar	
degree	to	individuals	with	organic	bowel	disorders,	such	as	Crohn's	
disease,12,13	 and	 co-existent	 mood	 disorders	 are	 common.14 This 
may	be	more	 pronounced	 for	 people	with	 IBS	with	 diarrhea	 (IBS-
D)	or	 IBS	with	mixed	stool	pattern	(IBS-M).15 These patients often 
report a fear of incontinence due to loose stools and urgency16 and 
can	therefore	find	working	and	socializing	extremely	challenging.17
General	 anxiety	 is	 common	 in	 IBS	 and	 is	 associated	 with	 in-
creased severity of gastrointestinal symptoms.18 This may reflect the 
fact	that	IBS	symptoms	are	worrisome	for	some	patients,	as	with	any	
other	chronic	disease,	and	that	this	anxiety	is	therefore	secondary	
to the physical condition.19	Alternatively,	anxiety	may	influence	pain	
perception by interfering with central systems involved in process-
ing	and	modulating	noxious	visceral	afferent	signals.20
In	 recent	 years,	 there	 has	 been	 interest	 in	 a	 specific	 form	 of	
anxiety,	termed	gastrointestinal	symptom-specific	anxiety,	which	is	
the	 fear	of	 the	potential	adverse	consequences	of	gastrointestinal	
symptoms,	as	opposed	to	general	anxiety,	which	involves	a	sense	of	
unease and fear about a wide range of situations and issues (which 
may	 include	 IBS).	 Gastrointestinal	 symptom-specific	 anxiety	 has	
been	measured	with	 a	 validated	 questionnaire,	 the	 visceral	 sensi-
tivity	 index	 (VSI).21	 Support	 for	 gastrointestinal	 symptom-specific	
anxiety	as	a	genuine	concept	 in	patients	with	 IBS	comes	 from	the	
fact	that	its	presence	seems	to	predict	a	diagnosis	of	IBS	with	good	
accuracy and that it appears to mediate the observed relationship 
between	measures	 of	 general	 anxiety	 and	 the	 severity	 of	 gastro-
intestinal symptoms.22	 The	VSI	was	developed	and	validated	on	a	
relatively	small	sample	of	subjects	with	IBS	in	the	USA,21 recruited 
by	advertisement,	and	a	further	validation	study	was	conducted	in	a	
group	of	Japanese	university	students,23 but its properties have not 
been	confirmed	in	a	UK	population.
It	 is	 well	 recognized	 that	 patients	 with	 IBS	 often	 complain	 of	
other	 extra-intestinal	 symptoms,24 the presence of which may be 
linked	to	mechanisms	of	central	sensitization.25	In	IBS,	somatization	
has been shown to predict both gastrointestinal symptom severity 
and	patient	consulting	behavior,26 and it is associated with most vis-
ceral sensitivity parameters.27	In	one	study,	general	anxiety	had	an	
indirect	effect	on	 IBS	symptom	severity,	via	somatization	and	cat-
astrophizing.28	 In	 the	 VSI	 validation	 study,	 the	 effects	 of	 general	
anxiety	on	 IBS	symptom	severity	were	mediated	via	gastrointesti-
nal	symptom-specific	anxiety.21	To	our	knowledge,	the	relationship	
between	general	anxiety,	gastrointestinal	symptom-specific	anxiety,	
and	somatization	has	not	been	fully	explored,	although	there	have	
been	 several	 relatively	 small	 cross-sectional	 studies	 that	 have	 ex-
amined	the	relationship	between	anxiety	and	gastrointestinal	symp-
tomatology.29-32	 In	 the	 present	 study,	 we	 first	 aimed	 to	 establish	
the	 factor	 structure	of	 the	VSI	 in	a	 large	UK	cohort	of	 individuals	
who	meet	the	current	gold	standard	for	diagnosing	 IBS,	 the	Rome	
IV	criteria,1	and	then	examined	the	relationship	between	IBS	symp-
tom	severity,	the	VSI	(and	its	different	factors),	general	anxiety,	and	
somatization.
2  | MATERIAL S AND METHODS
2.1 | Participants and setting
The	study	was	conducted	among	individuals	who	self-identified	as	
having	IBS	and	who	were	registered	with	three	organizations	in	the	
K E Y W O R D S
anxiety,	irritable	bowel	syndrome,	psychological	health,	Rome	IV	criteria,	somatization,	
symptoms
Key Points
•	 Gastrointestinal	 symptom-specific	 anxiety,	 measured	
using	the	visceral	sensitivity	index	(VSI),	and	somatiza-
tion have both been associated with higher symptom 
severity	in	patients	with	irritable	bowel	syndrome	(IBS).
•	 This	study	in	a	large	UK	population	of	patients	with	IBS	
has	 revealed	a	 three-factor	structure	of	 the	VSI.	Most	
VSI	 items	concerned	with	overt	gastrointestinal	symp-
tom-specific	 anxiety	 loaded	 onto	 the	 two	 VSI	 factors	
that	were	not	associated	with	IBS	symptom	severity.
• Our findings cast doubt on the central role of gas-
trointestinal	 symptom-specific	 anxiety	 as	 a	 driver	
for	 symptom	 severity	 in	 IBS.	 However,	 awareness	 of	
both	 gastrointestinal	 and	 extra-intestinal	 symptoms	 is	
strongly	associated	with	IBS	symptom	severity.
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UK.	The	methodology	has	been	described	elsewhere.33	Briefly,	we	
approached	 individuals	 registered	 with	 the	 IBS	 network,	 the	 reg-
istered	charity	 for	people	 living	with	 the	condition;	TalkHealth,	an	
online social health community providing information about vari-
ous	 medical	 conditions;	 and	 ContactMe-IBS,	 a	 dedicated	 register	
allowing	individuals	with	IBS	not	receiving	specialist	care	currently	
to participate in research. Individuals registered with these three 
organizations	were	provided	with	the	opportunity	to	access	a	ques-
tionnaire	 electronically,	 between	 December	 2017	 and	 December	
2018.	 There	were	 no	 exclusion	 criteria,	 other	 than	 an	 inability	 to	
understand	written	English.	The	University	of	Leeds	research	ethics	
committee	approved	the	study	in	November	2017.
2.2 | Data collection and synthesis
2.2.1 | Demographic and gastrointestinal 
symptom data
Participants	 provided	 basic	 demographic	 data,	 including	 age,	 gen-
der,	ethnicity,	marital	status,	educational	level,	and	lifestyle	(tobacco	
and	alcohol	use).	We	also	asked	respondents	to	state	whether	they	
had seen a primary care physician or a gastroenterologist with their 
IBS	symptoms.	Lower	gastrointestinal	symptom	data	were	collected	
using	 the	 Rome	 IV	 questionnaire.34 The presence or absence of 
Rome	IV-defined	IBS	among	all	individuals	was	assigned	according	to	
the	scoring	algorithms	proposed	for	use	with	the	Rome	IV	question-
naire,1	which	are	detailed	 in	Table	S1.	 IBS	subtypes	 (IBS	with	con-
stipation	 [IBS-C],	 IBS-D,	 IBS-M,	and	 IBS	unclassified	 [IBS-U])	were	
assigned	with	the	same	questionnaire.
We	assessed	the	severity	of	IBS	symptoms	using	the	IBS	severity	
scoring	system	(IBS-SSS).35	This	seven-item	self-administered	ques-
tionnaire	measures	presence,	severity,	and	frequency	of	abdominal	
pain,	 presence	 and	 severity	 of	 abdominal	 distension,	 satisfaction	
with	bowel	habit,	and	degree	to	which	IBS	symptoms	are	affecting,	
or	interfering	with,	the	person's	life	in	general.	The	maximum	score	is	
500	points:	<75	indicates	remission	of	symptoms;	75-174	mild	symp-
toms;	175-299	moderate	symptoms;	and	300-500	severe	symptoms.
2.2.2 | Assessment of mood and somatization
General	anxiety	and	depression	scores	were	collected	using	the	hos-
pital	anxiety	and	depression	scale	(HADS).36	The	total	HADS	score	
ranges	 from	0	 to	21	 for	either	 anxiety	or	depression.	Severity	 for	
each	was	categorized	into	normal	(total	HADS-depression	or	HADS-
anxiety	 score	 0-7),	 borderline	 normal	 (8-10),	 or	 above	 threshold	
(≥11).36	 Somatization	data	were	 collected	using	 the	patient	 health	
questionnaire-12	(PHQ-12),26	derived	from	the	PHQ-15,37 which in 
turn	is	derived	from	the	validated	full	PHQ.38	The	PHQ-12	excludes	
three	 items	 from	 the	PHQ-15	 that	 refer	 to	 gastrointestinal	 symp-
toms.	The	total	PHQ-12	score	ranges	from	0	to	24	and	only	includes	
extra-intestinal	symptoms.
2.2.3 | Assessment of gastrointestinal symptom-
specific anxiety
We	used	the	VSI,21	which	is	a	15-item	instrument	to	measure	gastro-
intestinal	symptom-specific	anxiety.	Replies	to	each	of	the	questions	
are	 provided	 on	 a	 six-point	 scale	 from	 “strongly	 disagree”	 (scored	
as	0)	to	“strongly	agree”	(scored	as	5).	As	mentioned	previously,	its	
developers reported a single factor structure in 100 patients with 
IBS	who	were	recruited	via	advertising,21 which was confirmed by a 
Japanese	study	that	used	the	measure	on	349	university	students.23 
As	the	VSI's	factor	structure	has	not	been	confirmed	using	a	UK	pop-
ulation,	we	undertook	a	preliminary	factor	analysis	of	the	measure	
prior to any further analyses.
2.3 | Statistical analysis
Statistical	 analysis	 was	 performed	 using	 SPSS	 (version	 26)	 and	 R	
(version	 3.6.3).	We	 used	 Pearson's	 correlation	 coefficients	 to	 de-
termine the strength and direction of simple relationships between 
total	IBS-SSS	score	and	age,	total	HADS-anxiety	score,	total	HADS-
depression	score,	total	PHQ-12	score,	and	total	VSI	score.	We	used	
exploratory	factor	analysis	to	investigate	the	potential	multidimen-
sionality	of	the	VSI	construct	in	our	study	dataset.	We	measured	ad-
equacy	of	exploratory	factor	analysis	using	the	Kaiser-Meyer-Olkin	
test,	which	 should	be	>0.60.39	We	used	parallel	 analysis,	which	 is	
the	most	 robust	 technique,	 to	 determine	 the	 number	 of	 retained	
extracted	 factors.40 Since it is important to ensure distinct factor 
loading	to	interpret	and	name	the	factors,	we	applied	factor	rotation	
using	oblique	techniques	to	maximize	factor	loading	on	each	factor.	
We	deleted	variables	with	 loadings	<0.30	 from	 the	corresponding	
factor.39	We	 used	Cronbach's	 alpha,	 the	measure	 of	 internal	 con-
sistency	(or	coefficient	of	reliability),	to	see	how	closely	related	the	
items	were	as	a	group	for	the	VSI.	Cronbach's	alpha	of	0.70	is	a	rea-
sonable threshold for the scale to be reliable.41
We	 also	 used	 partial	 correlations	 to	 explore	 relationships	 be-
tween	 the	 key	 variables	 that	may	 affect	 the	 performance	of	 later	
regression analyses. We then carried out a series of multiple linear 
regression analyses to determine the relationship between gastro-
intestinal	 symptom-specific	 anxiety	 according	 to	 the	 VSI,	 general	
anxiety	according	to	the	HADS,	somatization	via	the	PHQ-12,	and	
gastrointestinal	 symptom	 severity	measured	 using	 the	 IBS-SSS.	 In	
every	analysis,	 the	IBS-SSS	score	was	used	as	the	dependent	vari-
able,	and	sex,	age,	marital	status,	White	Caucasian	ethnicity,	and	a	
university or postgraduate level of education were entered as co-
founders	 in	 all	 analyses.	 As	 we	 found	 three	 different	 factors	 for	
the	VSI,	we	entered	each	of	the	factors	as	a	separate	independent	
variable	in	the	first	series	of	analyses,	together	with	HADS-anxiety	
score,	PHQ-12	score,	and	relevant	sociodemographic	characteristics.	
We carried out the analyses on the group as whole and then for the 
four	different	IBS	subtypes.	In	the	second	set	of	analyses,	we	used	
the	 total	VSI	score,	 instead	of	 the	 three	 factors,	and	repeated	the	
analyses	as	described	above.	We	estimated	both	the	unstandardized	
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regression coefficient (B),	showing	the	effect	of	predictors,	and	the	
standardized	coefficient	(β),	showing	the	relative	magnitude	of	pre-
dictors.	We	checked	model	assumptions	of	residuals	normality	and	
homogeneity.	We	checked	a	model	specification	error	for	including	
irrelevant variables in the model or omitting relevant variables from 
the model.
We	used	path	analysis	 to	examine	a	potential	mediating	effect	
for	 the	VSI	 on	 the	 relationship	 between	HADS-anxiety	 score	 and	
IBS-SSS	score,	as	has	been	reported	previously.21	Similarly,	we	also	
examined	 a	 potential	 mediating	 effect	 for	 the	 PHQ-12	 score	 on	
HADS-anxiety	score	and	IBS-SSS	score.
3  | RESULTS
Demographic	data	 for	 the	 cohort	 are	 summarized	 in	Table	1.	The	
mean	 age	 of	 the	 811	 included	 individuals	 was	 47.4	 years,	 697	
(85.9%)	 were	 female,	 and	 763	 (94.3%)	 were	 White	 Caucasian.	
Overall,	142	(17.5%)	participants	had	IBS-C,	311	(38.3%)	IBS-D,	331	
(40.8%)	IBS-M,	and	26	(3.2%)	IBS-U.	There	were	778	(95.9%)	people	
who	had	seen	their	primary	care	physician	with	their	IBS	symptoms,	
and	492	(60.7%)	who	had	seen	a	gastroenterologist.	The	mean	IBS-
SSS	was	292,	and	379	(46.8%)	of	the	individuals	had	severe	symp-
toms.	 The	 mean	 HADS-anxiety	 score	 was	 11.0,	 and	 442	 (54.5%)	
had	above	threshold	HADS-anxiety	scores	(≥11).	The	mean	HADS-
depression	 score	 was	 7.7,	 and	 186	 (22.9%)	 had	 above	 threshold	
HADS-depression	scores	(≥11).	The	mean	PHQ-12	score	was	10.3,	
and	the	mean	number	of	symptom	items	endorsed	on	the	PHQ-12	
was	7.1.	Finally,	the	mean	VSI	score	was	50.7;	369	(45.5%)	partici-
pants	agreed	strongly	with	five	or	more	of	the	15	items	on	the	VSI.
3.1 | Factor analysis of the VSI
The	Kaiser-Meyer-Olkin	measure	of	sampling	adequacy	of	explora-
tory	 factor	 analysis	 was	 0.94,	 above	 the	 recommended	 value	 of	
TA B L E  1  Demographics	and	psychosocial	characteristics	for	all	participants	and	for	individual	IBS	subtypes
 
Participants with 
Rome IV IBS (n = 811) IBS-C (n = 142) IBS-D (n = 311) IBS-M (n = 331) IBS-U (n = 26)
Mean	age	(SD) 47.4	(15.2) 46.1	(14.4) 47.9	(14.7) 46.6	(15.7) 57.5	(15.2)
Mean	body	mass	index	(SD) 28.4	(8.3) 25.9	(5.7) 29.6	(8.4) 28.2	(8.9) 27.8	(5.9)
Female	gender	(%) 697	(85.9) 126	(88.7) 258	(83.0) 291	(87.9) 21	(80.8)
Tobacco	user	(%) 79	(9.7) 19	(13.4) 29	(9.3) 31	(9.4) 0	(0)
Alcohol	user	(%) 442	(54.5) 72	(50.7) 184	(59.2) 175	(52.9) 11	(42.3)
Married	or	co-habiting	(%) 526	(64.9) 96	(67.6) 199	(64.0) 215	(65.0) 15	(57.7)
University	or	postgraduate	level	of	
education	(%)
315	(39.0) 56	(39.4) 133	(42.8) 117	(35.6) 9	(34.6)
White	Caucasian	ethnicity	(%) 763	(94.3) 138	(97.2) 297	(95.5) 302	(91.5) 26	(100)
Seen	a	primary	care	physician	with	IBS	(%) 778	(95.9) 133	(93.7) 300	(96.5) 318	(96.4) 26	(100)
Seen	a	gastroenterologist	with	IBS	(%) 492	(60.7) 84	(59.2) 193	(62.1) 193	(58.5) 21	(80.8)
IBS-SSS	symptom	severity	(%)
Remission 8	(1.0) 1	(0.7) 3	(1.0) 2	(0.6) 2	(7.7)
Mild 90	(11.1) 9	(6.3) 38	(12.2) 40	(12.1) 3	(11.5)
Moderate 333	(41.1) 59	(41.5) 131	(42.1) 130	(39.4) 12	(46.2)
Severe 379	(46.8) 73	(51.4) 139	(44.7) 158	(47.9) 9	(34.6)
Mean	IBS-SSS	score	(SD) 292.0	(95.8) 301.4	(86.9) 287.6	(96.3) 292.9	(96.9) 282.8	(122.8)
HADS-A	categories	(%)
Normal 202	(24.9) 32	(22.5) 89	(28.6) 73	(22.1) 8	(30.8)
Borderline 167	(20.6) 33	(23.2) 60	(19.3) 65	(19.6) 9	(34.6)
Abnormal 442	(54.5) 77	(54.2) 162	(52.1) 193	(58.3) 9	(34.6)
Mean	HADS-A	score	(SD) 11.0	(4.7) 11.3	(5.0) 10.6	(4.7) 11.3	(4.6) 9.8	(4.9)
HADS-D	categories	(%)
Normal 434	(53.5) 80	(56.3) 177	(56.9) 159	(48.0) 18	(69.2)
Borderline 191	(23.6) 23	(16.2) 64	(20.6) 101	(30.5) 2	(7.7)
Abnormal 186	(22.9) 39	(27.5) 70	(22.5) 71	(21.5) 6	(23.1)
Mean	HADS-D	score	(SD) 7.7	(4.5) 7.8	(4.8) 7.4	(4.7) 7.9	(4.1) 6.2	(4.5)
Mean	PHQ-12	score	(SD) 10.3	(4.3) 10.7	(4.6) 9.5	(4.0) 11.0	(4.4) 9.2	(4.9)
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0.60.	Using	 parallel	 analysis,	 three	 factors	were	 found	 to	 account	
for	47%	of	the	variance.	One	main	factor	(VSI	factor	one)	accounted	
for	21.1%	of	 the	variance,	with	the	second	factor	 (VSI	 factor	 two)	
accounting	for	16.5%,	and	the	third	factor	(VSI	factor	three)	10.0%.	
Table	2	 shows	 the	 items	and	 loadings	 for	each	of	 the	 factors.	VSI	
factor	one	comprised	items	1,	3,	4,	7,	and	10	of	the	VSI,	with	factor	
loadings	 from	0.55	 to	0.73,	 and	appeared	 to	be	best	described	as	
“awareness	of	 abdominal	 discomfort”.	VSI	 factor	 two	 consisted	of	
items	11,	12,	13,	and	15	with	loadings	from	0.60	to	0.91	and	included	
factors that predominantly related to worry and fear that gastroin-
testinal	symptoms	may	have	a	serious	underlying	cause.	VSI	factor	
three	consisted	of	items	2,	6,	and	9	with	loadings	between	0.39	and	
0.88,	which	were	all	 concerned	with	worries	or	 fears	of	how	new	
experiences	may	 impact	on	gastrointestinal	 symptoms.	 Items	5,	8,	
and	14	were	problematic,	since	they	showed	either	indistinct	or	low	
factor	 loading	 (<0.3),	 and	hence,	 they	were	not	 included	 in	any	of	
the	three	factors.	The	reliability	of	the	overall	VSI	and	the	three	ex-
tracted factors was above 0.70.
3.2 | Results of the regression analyses
In	 the	 univariate	 analyses,	 using	 simple	 correlation	 (r),	 the	 follow-
ing	variables	were	associated	with	total	IBS-SSS	score:	total	HADS-
anxiety	score	(r	=	.262,	P-value	<.001);	total	HADS-depression	score	
(r	=	 .335,	P-value	<.0001);	PHQ-12	score	(r	=	 .408,	P-value	<.001);	
total	VSI	score	(r	=	.364,	P-value	<.001);	and	age	(r	=	−.130,	P-value	
<.001).	Partial	correlations	involving	the	main	variables	and	IBS-SSS	
showed	no	major	differences	to	the	full	correlation	matrix,	with	the	
exception	 of	 the	 effects	 of	 total	HADS-depression	 score	 on	 total	
Factors and items
Loadings for 
Factor 1
Loadings for 
Factor 2
Loadings for 
Factor 3
Factor 1: worry and/or awareness of abdominal discomfort
Item 1: I worry that whenever I eat 
during	the	day,	bloating	and
0.55   
Item 3: I often worry about problems in 
my belly distension in my belly will get 
worse
0.66   
Item	4:	I	have	a	difficult	time	enjoying	
myself because I cannot get my mind 
off of discomfort in my belly
0.65   
Item	7:	No	matter	what	I	eat,	I	will	
probably feel uncomfortable
0.73   
Item 10: I am constantly aware of the 
feelings I have in my belly
0.68   
Factor 2: fear of serious illness
Item 11: I often feel discomfort in my 
belly could be a sign of serious illness
 0.69  
Item	12:	As	soon	as	I	awake,	I	worry	that	
I will have discomfort in my belly during 
the day
 0.60  
Item 13: When I feel discomfort in my 
belly,	it	frightens	me
 0.91  
Item	15:	I	constantly	think	about	what	is	
happening inside my belly
 0.62  
Factor	3:	Fear	of	new	experiences
Item	2:	I	get	anxious	when	I	go	to	a	new	
restaurant
  0.88
Item	6:	Because	of	fear	of	developing	
abdominal	discomfort,	I	seldom	try	new	
foods
  0.48
Item	9.	When	I	enter	a	place	I	haven't	
been	before,	one	of	the	first	things	I	do	
is	look	for	a	bathroom
  0.39
Proportion	variation 21.1% 16.5% 10.0%
Kaiser-Meyer-Olkin	measure 0.94
Cronbach's alpha 0.86 0.89 0.74
0.92	(overall)
TA B L E  2   Items	of	the	VSI	according	
to	a	three-factor	solution,	using	oblique	
rotation	techniques,	with	corresponding	
factor	loadings,	Kaiser-Meyer-Olkin	
measure and Cronbach's alpha
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TA B L E  3  Regression	models	for	all	participants	with	IBS,	and	according	to	subtype,	with	IBS-SSS	score	as	the	dependent	variable	and	the	
three-factor	VSI	included	as	an	independent	variablea
 B β t
P-
value 95% CI for B
All	participants	meeting	Rome	IV	criteria	for	IBS	(n	=	811)
VSI	factor	one:	worry	and/or	awareness	of	
abdominal discomfort
6.03 0.42 8.17 <.001 4.58	to	7.48
VSI	factor	two:	fear	of	serious	illness −0.41 −0.025 −0.54 .586 −1.87	to	1.06
VSI	factor	three:	fear	of	new	experiences −2.08 −0.09 −2.21 .27 −3.93	to	−0.23
PHQ-12 6.79 0.31 8.87 <.001 5.29	to	8.30
HADS-anxiety −4.55 −0.04 −1.15 .253 −12.34	to	3.25
Constant 109.31  4.15 <.001 57.66	to	161
 R2	=	28.5%	R2-adjusted%	=	27.6%	F	(ANOVA)	=	31.63	P-value	<.001
Participants	with	IBS-C	(n	=	142)
VSI	factor	one:	worry	and/or	awareness	of	
abdominal discomfort
4.89 0.37 3.05 .003 1.72 to 8.07
VSI	factor	two:	fear	of	serious	illness −0.31 −0.02 −0.18 .86 −3.66	to	3.04
VSI	factor	three:	fear	of	new	experiences −1.88 −0.095 −0.96 .34 −5.78	to	2.01
PHQ-12 7.90 0.42 4.15 <.001 4.39	to	11.41
HADS-anxiety −11.33 −0.11 −1.19 .24 −30.23	to	7.57
Constant 114.59  1.75 .08 −14.73	to	244
 R2	=	28.1%	R2-adjusted%	=	22.6%	F	(ANOVA)	=	5.11	P-value	<.001
Participants	with	IBS-D	(n	=	311)
VSI	factor	one:	worry	and/or	awareness	of	
abdominal discomfort
7.24 0.49 5.98 <.001 4.86	to	9.63
VSI	factor	two:	fear	of	serious	illness −0.20 −0.01 −0.18 .86 −2.43	to	2.03
VSI	factor	three:	fear	of	new	experiences −0.87 −0.037 −0.575 .565 −3.86	to	2.12
PHQ-12 5.75 0.24 4.52 <.001 3.25	to	8.25
HADS-anxiety −1.70 −0.015 −0.29 .77 −13.21	to	9.82
Constant 88.71  1.75 .08 −14.73	to	244
 R2	=	37.8%	R2-adjusted%	=	35.7%	F	(ANOVA)	=	18.25	P-value	<.001
Participants	with	IBS-M	(n	=	331)
VSI	factor	one:	worry	and/or	awareness	of	
abdominal discomfort
5.09 0.35 4.27 <.001 2.74	to	7.44
VSI	factor	two:	fear	of	serious	illness −0.96 −0.06 −0.76 .45 −3.46	to	1.53
VSI	factor	three:	fear	of	new	experiences −2.50 −0.10 −1.50 .13 −5.77	to	0.78
PHQ-12 6.73 0.30 5.40 <.001 4.28	to	9.19
HADS-anxiety −1.20 −0.01 −0.18 .86 −14.45	to	12.05
Constant 108.79  2.35 .02 17.79	to	200
 R2	=	22.4%	R2-adjusted%	=	20.0%	F	(ANOVA)	=	9.11	P-value	<.001
Participants	with	IBS-U	(n	=	26)
VSI	factor	one:	worry	and/or	awareness	of	
abdominal discomfort
19.29 0.93 3.56 .003 7.79	to	30.80
VSI	factor	two:	fear	of	serious	illness −5.05 −0.28 −1.12 .28 −14.63	to	4.54
VSI	factor	three:	fear	of	new	experiences −7.59 −0.22 −1.43 .17 −18.89	to	3.70
PHQ-12 13.88 0.55 3.99 .001 6.51	to	21.25
HADS-anxiety −62.44 −0.42 −2.03 .06 −127.5	to	2.63
Constant −11.99  −0.09 .93 −290	to	266
 R2	=	79.2%	R2-adjusted%	=	67.5%	F	(ANOVA)	=	6.79	P-value	<.001
aControl	variables	are:	sex,	age,	marital	status,	White	Caucasian	ethnicity,	and	university	or	postgraduate	education.	
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HADS-anxiety	 score.	 The	 presence	 of	 HADS-depression	 reduced	
the	 correlation	 between	 total	 HADS-anxiety	 and	 total	 IBS-SSS	
(r = .067 P-value	=	 .57),	whereas	HADS-anxiety	appeared	 to	have	
little	effect	on	the	relationship	between	total	HADS-depression	and	
total	IBS-SSS	(r	=	.226,	P-value	<.001).	Checking	model	specification	
error	 for	omitting	variables,	 total	HADS-depression	was	 irrelevant	
to	the	model.	For	this	reason,	 in	the	main	regression	analyses,	this	
was	excluded.
The	 results	 of	 the	main	 regression	 analyses,	 for	 all	 individuals	
and	by	IBS	subtype,	are	shown	in	Table	3.	For	each	model,	the	three	
factors	of	the	VSI	were	entered	separately,	plus	HADS-anxiety	score	
and	 the	 PHQ-12	 score.	 Sociodemographic	 characteristics	 (gender,	
age,	ethnicity,	and	educational	 level)	were	 included	as	cofounders.	
VSI	 factor	 one	 and	 PHQ-12	 were	 the	 only	 variables	 that	 had	 an	
independent	significant	association	with	IBS-SSS,	and	this	was	true	
for	the	group	as	a	whole	and	for	all	four	IBS	subtypes.	Neither	VSI	
factor	two	nor	VSI	factor	three	showed	any	significant	association	
with	IBS-SSS.	The	results	for	the	26	individuals	in	the	IBS-U	subtype	
were	less	robust	than	for	the	other	three,	as	the	95%	confidence	in-
tervals for the B	coefficients	were	very	wide,	which	probably	relates	
to	the	smaller	number	of	participants,	in	comparison	with	the	other	
three subtypes.
All	 the	 above	 analyses	 were	 then	 re-run	 for	 the	 group	 as	 a	
whole	 and	 for	 all	 four	 IBS	 subtypes,	with	 the	 total	VSI	 score	 in-
cluded,	instead	of	the	three-factor	version	(Table	4).	The	total	VSI	
score	and	the	PHQ-12	score	were	independently	associated	with	
the	 IBS-SSS	score	for	the	group	as	a	whole	and	each	of	the	 indi-
vidual	 IBS	subtypes.	The	variance	explained	using	VSI	factor	one	
 B β t P-value 95% CI for B
All	participants	meeting	Rome	IV	criteria	for	IBS	(n	=	811)
VSI 1.88 0.29 8.16 <.001 1.43	to	2.33
HADS-anxiety −0.456 −0.02 −0.60 .55 −1.96	to	1.04
PHQ-12 6.84 0.31 8.57 <.001 5.27	to	8.40
Constant 133.330  5.01 <.001 81.09	to	186
 R2	=	25.2%	R2-adjusted%	=	24.5%	F	(ANOVA)	=	33.65	P-value	<.001
Participants	with	IBS-C	(n	=	142)
VSI 1.76 0.30 3.13 .002 0.65	to	2.89
HADS-anxiety −2.72 −0.16 −1.60 .11 −6.09	to	0.65
PHQ-12 7.39 0.39 4.15 <.001 3.87	to	10.91
Constant 149.64  2.25 .03 18.15	to	281
 R2	=	25.5%	R2-adjusted%	=	21.1%	F	(ANOVA)	=	5.70	P-value	<.001
Participants	with	IBS-D	(n	=	311)
VSI 2.79 0.425 7.74 <.001 2.08	to	3.50
HADS-anxiety −0.80 −0.039 −0.69 .49 −3.09	to	1.48
PHQ-12 6.43 0.26 4.90 <.001 3.85	to	9.01
Constant 117.17  2.93 .004 38.55	to	196
 R2	=	34.7%	R2-adjusted%	=	33.0%	F	(ANOVA)	=	20.10	P-value	<.001
Participants	with	IBS-M	(n	=	331)
VSI 1.13 0.17 3.06 .002 0.41	to	1.86
HADS-anxiety 1.03 0.049 0.81 .42 −1.47	to	3.53
PHQ-12 6.44 0.29 4.97 <.001 3.89	to	8.90
Constant 122.88  2.64 .009 31.33	to	214
 R2	=	20.0%	R2-adjusted%	=	18.0%	F	(ANOVA)	=	9.92	P-value	<.001
Participants	with	IBS-U	(n	=	26)
VSI 3.79 0.48 2.47 .024 0.57	to	7.02
PHQ-12 −2.20 −0.09 −0.37 .72 −14.76	to	
10.36
HADS-anxiety 14.68 0.58 3.41 .003 5.63	to	23.73
Constant 184.84  1.47 .16 −78.64	to	
448
 R2	=	65.5%	R2-adjusted%	=	52.1%	F	(ANOVA)	=	4.88	P-value	=	.003
aControl	variables	are:	sex,	age,	marital	status,	White	Caucasian	ethnicity,	and	university	or	
postgraduate education. 
TA B L E  4   Regression models for all 
participants	with	IBS,	and	according	
to	subtype,	with	IBS-SSS	score	as	the	
dependent	variable	and	total	VSI	included	
as an independent variablea
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was	 slightly	 better	 than	 using	 total	VSI	 score	 for	 the	 group	 as	 a	
whole	(27.6%	vs	24.5%)	and	the	individual	subtypes	(IBS-C	22.6%	
vs	21.1%;	IBS-D	35.7%	vs	33.0%;	IBS-M	20.0%	vs	18.0%).	General	
anxiety,	as	measured	by	the	HADS-anxiety	score,	was	not	signif-
icant in any of the models. The results of path analysis indicated 
that	there	was	no	mediating	effect	for	total	VSI,	VSI	factor	one,	or	
PHQ-12	on	the	HADS-anxiety	score	and	the	IBS-SSS	score.
4  | DISCUSSION
IBS	is	a	chronic	disease,	which	is	now	viewed	as	a	disorder	of	gut-
brain	interaction,42	and	patients	often	exhibit	psychological	comor-
bidity,14,18,43,44	although	whether	this	is	a	cause	or	consequence	of	
gastrointestinal symptoms is unclear.45,46	It	is	reasonable	to	expect	
that patients with the highest symptom burden will have the high-
est	 levels	 of	 psychological	 problems.	However,	 there	 is	 increasing	
evidence	that	mood	problems	can	drive	IBS	symptoms,45,46 and ther-
apies	 designed	 to	 improve	 psychological	 health,	 such	 as	 cognitive	
behavioral	 therapy,7,47	or	gut-directed	hypnotherapy,48 can lead to 
symptom improvement for some patients. It is therefore important 
to understand these interactions and to better elucidate the rela-
tionship	between	anxiety,	both	general	and	gastrointestinal	symp-
tom-specific,	and	symptoms	of	IBS.
We	have	done	this	in	a	large	cohort	of	individuals	with	IBS,	de-
fined	according	to	the	Rome	IV	criteria.	Almost	50%	of	participants	
endorsed	five	or	more	of	the	15	items	on	the	VSI,	54.5%	had	above	
threshold	HADS-anxiety	scores,	and	more	than	one	in	five	had	above	
threshold	HADS-depression	 scores,	with	mean	HADS-anxiety	 and	
depression	scores	of	11.0	and	7.7,	 respectively.	The	mean	 IBS-SSS	
score	was	292,	and	almost	50%	of	participants	had	a	score	of	≥300,	
indicating severe symptoms. These findings are consistent with a 
clinical	population	of	IBS	sufferers.
Our	 factor	 analysis	 of	 the	 VSI	 found	 a	 three-factor	 solution,	
rather	than	a	single	factor	structure.	VSI	factor	one	included	three	
items concerned with discomfort (“I am constantly aware of the 
feelings	 I	 have	 in	my	belly,”	 “No	matter	what	 I	 eat,	 I	will	 probably	
feel	 uncomfortable,”	 and	 “I	 have	 a	 difficult	 time	 enjoying	 myself	
because	 I	 cannot	get	my	mind	off	of	discomfort	 in	my	belly”)	 and	
two items concerned with worry about gastrointestinal symptoms 
(“I	worry	 that	whenever	 I	 eat	during	 the	day,	 bloating	 and	disten-
sion in my belly will get worse” and “I often worry about problems 
in	 my	 belly”).	 The	 second	 and	 third	 factors	 included	 items	 much	
more	overtly	 related	to	anxiety	and	fear.	VSI	 factor	 two	consisted	
of items concerned with worry and fear about the potential serious 
consequences	 of	 gastrointestinal	 symptoms,	 and	 VSI	 factor	 three	
consisted of three items concerned with worries about coping with 
gastrointestinal symptoms in new environments. The three items 
which	were	not	included	in	any	of	the	three	factors	(items	5,	8,	and	
14)	were	concerned	with	worry,	 fear,	and	stress	 (“I	often	fear	that	
I	won't	be	able	 to	have	a	normal	bowel	movement,”	 “As	 soon	as	 I	
feel	abdominal	discomfort	I	begin	to	worry	and	feel	anxious,”	and	“In	
stressful	situations	my	belly	bothers	me	a	lot”).
The	further	analyses	we	conducted	suggest	that	only	VSI	factor	
one	was	 independently	 associated	with	 IBS	 symptom	 severity.	As	
with	other	investigators,	we	found	that	general	anxiety	was	not	an	
independent	predictor	of	 IBS	symptom	severity.21 We did not find 
any	evidence	 that	either	 total	VSI	or	VSI	 factor	one	mediated	 the	
relationship	between	HADS-anxiety	scores	and	total	IBS-SSS,	which	
is in contrast to previous investigators.21	Our	findings	question	the	
strength	of	the	association	between	so-called	gastrointestinal-spe-
cific	 anxiety	 and	 IBS	 symptom	severity,	 as	 the	 items	most	overtly	
associated	with	fear	and	anxiety	about	gastrointestinal	symptoms	in	
the	total	VSI	were	not	included	in	VSI	factor	one,	which	was	the	only	
factor	that	was	significantly	associated	with	IBS	symptom	severity	
in	 the	 regression	 analyses.	 It	 appears	 that	 neither	 general	 anxiety	
nor	most	of	the	items	on	the	VSI	are	independently	associated	with	
IBS	symptom	severity.	An	awareness	of	gastrointestinal	symptoms	
and	 feelings	of	 discomfort	 from	gastrointestinal	 symptoms,	 rather	
than	overt	fear	and	anxiety,	appear	to	be	more	likely	to	be	associated	
with	IBS	symptom	severity	and	may	therefore	reflect	a	tendency	to	
focus	on	more	severe	physical	symptoms,	rather	than	a	fear	of	their	
consequences	or	recurrence.
The	PHQ-12	was	 independently	 associated	with	 IBS	 symptom	
severity	in	all	the	analyses,	whether	total	VSI	score	or	the	three-fac-
tor	VSI	was	used,	and	for	all	the	IBS	subtypes.	This	 instrument	re-
cords	the	tendency	to	report	extra-intestinal	symptoms	and	is	used	
as	a	measure	of	somatization.	However,	there	is	increasing	evidence	
that	 IBS	 is	associated	with	atopic	and	 immune	disorders,49,50 so in 
some	cases,	this	may	represent	overlap	between	IBS	and	these	other	
conditions,	rather	than	somatoform-behavior	per	se.	Although	other	
investigators	have	found	that	depressed	and	anxious	patients	with	
IBS	are	more	likely	than	non-depressed	or	anxious	patients	to	have	
higher	 IBS	severity	scores,	higher	PHQ-12	scores,	and	higher	total	
VSI	 scores,51	 the	 central	 driver	 of	 IBS	 symptom	 severity	 appears	
to	 be	 the	 tendency	 to	 report	 or	 experience	 both	 gastrointestinal	
and	extra-intestinal	symptoms.	Both	general	anxiety,	measured	by	
HADS,	and	gastrointestinal	symptom-specific	anxiety,	as	measured	
by	the	total	VSI	score,	were	highly	prevalent	in	our	large	sample	of	
people	with	IBS.	Although	general	anxiety	and	anxiety	and/or	fear	
about	 IBS	may	 not	 be	 independently	 associated	with	 the	 severity	
of	gastrointestinal	symptoms,	evidence	suggests	that	they	still	play	
an	important	role	 in	the	impact	IBS	has	on	coping29	and	quality	of	
life.30,31
As	our	study	is	cross-sectional	in	nature,	we	are	unable	to	com-
ment on the direction of the associations we have observed. Other 
studies of identical design have demonstrated similar associations 
between	gastrointestinal	 symptom-specific	anxiety	and	 IBS	symp-
tom	severity,22,29,31	but	these	did	not	examine	the	factor	structure	
of	the	VSI	prior	to	their	analysis.	In	the	only	longitudinal	study	con-
ducted,	to	date,	which	recruited	276	patients	with	Rome	II-defined	
IBS,	 gastrointestinal	 symptom-specific	 anxiety	 predicted	 future	
deterioration	in	both	symptom	severity	and	quality	of	life,	whereas	
mood	 did	 not	 appear	 to	 impact	 on	 either	 symptoms	 or	 quality	 of	
life.52	 An	 alternative	 hypothesis	 is	 that	 these	 effects	 are	 bidirec-
tional,	 as	has	been	observed	 in	 studies	examining	 the	 relationship	
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between psychological health and symptoms in patients with both 
functional and organic gastrointestinal disorders.45,46,53
Strengths	of	this	study	include	the	sample	size	and	representa-
tiveness	of	 the	population.	A	 large	number	of	 individuals	were	re-
cruited,	all	of	whom	were	 in	the	community	and	met	the	Rome	IV	
criteria	for	 IBS.	Because	some	 individuals	had	consulted	a	primary	
care	physician,	some	a	gastroenterologist,	and	some	had	never	con-
sulted	a	physician,	the	participants	are	likely	to	be	generalizable	to	
many	individuals	living	with	IBS	in	the	UK.	Due	to	our	use	of	an	on-
line	questionnaire,	 data	 collection	was	near	 complete	 for	many	of	
the	variables	of	interest,	even	in	our	logistic	regression	models.	We	
used	parallel	analysis	in	our	factor	analysis	of	the	VSI	to	determine	
number	of	extracted	factors.	We	also	removed	three	gastrointestinal	
symptoms	from	the	PHQ-15,37	converting	it	to	the	PHQ-12,26 to en-
sure	it	was	not	measuring	gastrointestinal	symptomatology.	Finally,	
we	used	validated	questionnaires	 to	collect	gastrointestinal	 symp-
toms,	mood,	and	gastrointestinal	symptom-specific	anxiety	and	uti-
lized	the	Rome	IV	criteria	to	define	IBS,	the	current	gold	standard.1
Weaknesses	of	the	study	include	the	fact	that	we	did	not	confirm	
the	diagnosis	of	IBS	in	all	individuals	in	this	study	by	looking	at	their	
medical	records.	Instead,	we	relied	on	the	fact	that	people	who	met	
the	Rome	IV	criteria	were	likely	to	have	IBS	as	a	cause	of	their	lower	
gastrointestinal symptoms. This may mean that we included some 
people with organic diseases such as celiac disease or inflammatory 
bowel	disease,54-56	rather	than	true	IBS,	although	as	the	prevalence	
of	these	conditions	in	the	community	is	much	lower	than	IBS,	this	is	
unlikely	to	have	had	any	major	impact	on	our	results.	Although	this	
is	a	limitation,	our	methodology	is	similar	to	that	used	in	numerous	
population-based	studies	that	have	estimated	the	prevalence	of	IBS	
in	community	subjects,2	and	even	studies	examining	yield	of	colo-
noscopy	in	patients	meeting	criteria	for	IBS	in	secondary	care	report	
a low prevalence of organic disease.57,58	In	addition,	given	that	the	
respondents	 in	 this	 survey	believed	 they	had	 IBS,	were	 registered	
with	three	organizations	that	provide	services	to	people	living	with	
IBS,	and	as	a	high	proportion	had	seen	either	a	primary	care	physi-
cian	or	a	gastroenterologist	with	their	IBS,	we	feel	it	is	likely	that	the	
vast	majority	 of	 respondents	 genuinely	 had	 IBS.	As	 the	 question-
naire	was	completed	online,	we	are	unable	to	assess	how	many	in-
dividuals	chose	not	to	complete	the	questionnaire	or	whether	those	
who	responded	are	broadly	representative	of	all	the	people	with	IBS	
registered	with	these	three	organizations.	It	is	possible	that	individ-
uals	choosing	to	register	with	these	organizations	might	have	more	
troublesome	IBS	symptoms	than	average,	but	alternatively	their	in-
volvement may indicate that they are more engaged with their ill-
ness,	and	therefore	actively	seeking	treatment.	Indeed,	only	patients	
who	are	bothered	by	their	symptoms	are	likely	to	seek	the	advice	of	
a	doctor,	and	these	are	the	most	relevant	patients	to	understand	for	
clinical	 practice.	Moreover,	 these	patients	 are	 drawn	 from	a	 com-
munity	setting,	 rather	 than	being	 identified	using	a	hospital-based	
survey	and,	consequently,	are	likely	to	be	more	representative	of	the	
spectrum	of	 IBS	patients	as	a	whole.	 Indeed,	40%	of	patients	had	
not seen a gastroenterologist. Due to the setting in which this study 
was	conducted,	and	the	fact	that	participants	had	to	have	internet	
access,	 the	 individuals	 taking	part	may	not	be	generalizable	to	pa-
tients consulting with a gastroenterologist in secondary or tertiary 
care.	We	 feel	 this	 is	 unlikely,	 as	 a	 large	proportion	had	previously	
consulted	in	this	setting.	Finally,	as	the	vast	majority	of	respondents	
were	White	Caucasians,	the	results	cannot	be	extrapolated	to	indi-
viduals	with	IBS	of	other	ethnicities.
Our	 findings	suggest	 that	 further	work	 is	 required	to	establish	
the	 factor	structure	of	 the	VSI.	We	recommend	that	 future	 inves-
tigators who use this instrument assess its factor structure prior to 
any	further	analysis,	at	least	until	a	consistent	structure	can	be	es-
tablished. The direction of the associations we have found in this 
study	between	the	PHQ-12	score,	VSI	factor	one,	and	IBS-SSS	score	
can	only	be	addressed	by	 future	 longitudinal	 studies.	Additionally,	
greater	attention	should	be	played	to	extra-intestinal	symptoms	in	
IBS,	particularly	in	relation	to	overall	treatment	outcomes.	It	is	pos-
sible	that	stratifying	patients	using	questionnaire	tools	such	as	the	
PHQ-12	or	the	VSI,	in	addition	to	gastrointestinal	symptoms,	might	
be	 useful	 in	 tailoring	 treatment,	 but	 this	 concept	 requires	 further	
investigation.	Our	findings	question	the	previously	reported	key	role	
of	gastrointestinal-specific	anxiety	as	a	driver	of	symptom	severity	
in	IBS.	The	number	of	extra-intestinal	symptoms	and	an	awareness	
of,	or	focus	on,	abdominal	symptoms	were	most	strongly	associated	
with	 IBS	 symptom	 severity	 in	 the	present	 study.	We	 suggest	 that	
interventions	 designed	 to	 treat	 gastrointestinal	 symptom-specific	
anxiety	may	be	less	helpful	in	reducing	IBS	symptom	severity	than	
previously	 supposed,	 although	 they	may	 still	 help	 with	 improving	
quality	of	life.
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